ABBV

AbbVie Inc

Add to Watchlist

Advanced Chart

196.300

-2.25(-1.133%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

198.050

Open

197.230

VWAP

196.13

Vol

4.06M

Mkt Cap

346.78B

Low

194.670

Amount

795.76M

EV/EBITDA(TTM)

15.43

Total Shares

1.77B

414.81B

EV/OCF(TTM)

21.51

P/S(TTM)

6.03

AbbVie Inc. is a global, diversified research-based biopharmaceutical company. The Company is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Its Immunology products include rheumatology, dermatology and gastroenterology. Its Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere, and Epkinly. The Company’s Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Its Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and Other eye care. Its Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its Venclexta is a B-cell lymphoma 2 (BCL-2) inhibitor used to treat blood cancers.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

14.44B

+8.25%

2.925

+18.9%

16.34B

+8.22%

3.333

+54.32%

15.59B

+7.83%

3.285

+9.5%

Estimates Revision

The market is revising Upward the revenue expectations for AbbVie Inc. (ABBV) for FY2025, with the revenue forecasts being adjusted by 0.17% over the past three months. During the same period, the stock price has changed by 4.36%.

Revenue Estimates for FY2025

Revise Upward

+0.17%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-1.63%

In Past 3 Month

Stock Price

Go Up

+4.36%

In Past 3 Month

18 Analyst Rating

8.06% Upside

Wall Street analysts forecast ABBV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABBV is 212.13 USD with a low forecast of 170.00 USD and a high forecast of 250.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

12 Buy

6 Hold

0 Sell

Moderate Buy

8.06% Upside

Current: 196.300

Low

170.00

Averages

212.13

High

250.00

8.06% Upside

Current: 196.300

Low

170.00

Averages

212.13

High

250.00

Raymond James

Outperform

maintain

$227 -> $236

2025-08-01

Reason

Raymond James

Price Target

$227 -> $236

2025-08-01

maintain

Outperform

Reason

Raymond James raised the firm's price target on AbbVie to $236 from $227 and keeps an Outperform rating on the shares. AbbVie delivered a very solid Q2 with nice top- and bottom-line beats, and raised 2025 guidance for the second time this year driven by the strong momentum with most key growth drivers like Skyrizi and Neuro, the analyst tells investors in a research note. Aesthetics was soft as anticipated and continues to be hampered by macro headwinds that are persisting, so it's prudent to remain cautious with that franchise though AbbVie is still optimistic it will turn around longer-term, the firm says.

Evercore ISI

Gavin Clark-Gartner

Outperform

maintain

$205 -> $207

2025-08-01

Reason

Evercore ISI

Gavin Clark-Gartner

Price Target

$205 -> $207

2025-08-01

maintain

Outperform

Reason

Evercore ISI analyst Gavin Clark-Gartner raised the firm's price target on AbbVie to $207 from $205 and keeps an Outperform rating on the shares. AbbVie showed strong confidence in their neuro franchise, with positive sentiment around early-stage business development, while the reported, potential Gilgamesh acquisition could be "a boon for the psychedelics sector, with positive regulatory signals and strong data translating across mechanisms of action," the analyst tells investors.

Guggenheim

Buy

maintain

$216 -> $227

2025-08-01

Reason

Guggenheim

Price Target

$216 -> $227

2025-08-01

maintain

Buy

Reason

Guggenheim raised the firm's price target on AbbVie to $227 from $216 and keeps a Buy rating on the shares following what the firm calls "another strong quarter." Management raised full-year revenue and EPS guidance for the second time this year, adds the analyst, who update the firm's model to reflect higher Skyrizi and neuroscience estimates, a steeper Humira erosion curve, and slightly lower aesthetics estimates.

Citi

Buy

Neutral

downgrade

$210 -> $205

2025-05-14

Reason

Citi

Price Target

$210 -> $205

2025-05-14

downgrade

Buy

Neutral

Reason

Citi downgraded AbbVie to Neutral from Buy with a price target of $205, down from $210. While the company's current fundamentals are solid, the share impact from quarterly surprises could diminish going forward, especially as investors increasingly shift more focus to AbbVie's pipeline, the analyst tells investors in a research note. Citi cites the company's "comparatively lighter late-stage" pipeline versus its biopharma peers and a higher perceived policy risk than peers for the downgrade. Both of these add risk to AbbVie's "relative safety positioning," contends the firm.

Cantor Fitzgerald

Carter Gould

Buy

Initiates

$210

2025-04-22

Reason

Cantor Fitzgerald

Carter Gould

Price Target

$210

2025-04-22

Initiates

Buy

Reason

Cantor Fitzgerald analyst Carter Gould initiated coverage of AbbVie with an Overweight rating and $210 price target. AbbVie offers a "compelling mix of growth and defense" with a differentiated sales growth profile, good visibility on key near-term drivers with low clinical risk, no major near-to-mid-term loss of exclusivity with "the Humira pain behind it," and a lack of a major binary data catalyst over 2025, the analyst tells investors.

Guggenheim

Vamil Divan

Strong Buy

Reiterates

$214

2025-04-17

Reason

Guggenheim

Vamil Divan

Price Target

$214

2025-04-17

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for AbbVie Inc (ABBV.N) is 14.91, compared to its 5-year average forward P/E of 12.28. For a more detailed relative valuation and DCF analysis to assess AbbVie Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Fair

5Y Average PE

12.28

Current PE

14.91

Overvalued PE

15.25

Undervalued PE

9.30

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Overvalued

5Y Average EV/EBITDA

11.59

Current EV/EBITDA

13.77

Overvalued EV/EBITDA

13.55

Undervalued EV/EBITDA

9.63

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Overvalued

5Y Average PS

4.61

Current PS

5.60

Overvalued PS

5.51

Undervalued PS

3.70

Financials

Annual

Quarterly

FY2025Q2

YoY :

+6.65%

15.42B

Total Revenue

FY2025Q2

YoY :

+14.71%

5.72B

Operating Profit

FY2025Q2

YoY :

-31.46%

941.00M

Net Income after Tax

FY2025Q2

YoY :

-31.17%

0.53

EPS - Diluted

FY2025Q2

YoY :

+140.59%

4.88B

Free Cash Flow

FY2025Q2

YoY :

+1.24%

71.82

Gross Profit Margin - %

FY2025Q2

YoY :

-3.28%

31.27

FCF Margin - %

FY2025Q2

YoY :

-35.72%

6.10

Net Margin - %

FY2025Q2

YoY :

-14.75%

8.15

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

25.7M

USD

6-9

Months

32.4M

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

76.0K

Volume

6-9

Months

192.1K

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

26.4K

Volume

Months

6-9

2.1M

Volume

Months

0-12

57.3K

Volume

Months

Congress Trading

Congress areBuying! The buying amount has increased126.56%over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

174.0K

USD

6-9

Months

0.0

USD

0-12

Months

8.0K

USD

Bought

0-3

0.0

USD

Months

3-6

120.5K

USD

Months

6-9

115.0K

USD

Months

0-12

24.0K

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

25.7M

USD

6-9

Months

32.4M

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

ABBV News & Events

Events Timeline

2025-07-31 (ET)

2025-07-31

13:50:21

Trump posts letters calling on drug company CEOs to lower prices

2025-07-31

09:58:03

AbbVie says 'fairly insulated' from any tariff impacts this year

2025-07-31

09:32:46

AbbVie sees FY25 adjusted gross margin 84% of sales

News

8.0

08-06Yahoo Finance

Hungary's Richter says some US exports face tariff challenges, but flagship drug exempt

1.0

08-06PRnewswire

Get Ready, JUVÉDERM® Day is Calling!

8.0

08-06Benzinga

Trump Threatens Pharma With Potential 250% Tariffs In 18 Months: 'We Want Pharmaceuticals Made In Our Country'

People Also Watch

Taiwan Semiconductor Manufacturing Co Ltd

Berkshire Hathaway Inc

FAQ

What is AbbVie Inc (ABBV) stock price today?

The current price of ABBV is 196.3 USD — it has decreased -1.13 % in the last trading day.

ABBV

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

ABBV News & Events

Events Timeline

News

People Also Watch

FAQ

What is AbbVie Inc (ABBV) stock price today?

What is AbbVie Inc (ABBV)'s business?

What is the price predicton of ABBV Stock?

What is AbbVie Inc (ABBV)'s revenue for the last quarter?

What is AbbVie Inc (ABBV)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for AbbVie Inc (ABBV)'s fundamentals?

How many employees does AbbVie Inc (ABBV). have?

What is AbbVie Inc (ABBV) market cap?